ArticleHeart (British Cardiac Society)2006
Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care.
Article in Heart (British Cardiac Society), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 3 syntheses or guidelines pooled it, 166 citations in OpenAlex.
- Pooled it
- Cardiovascular medication utilization and adherence among adults living in rural and urban areas: a systematic review and meta-analysis.BMC public health · 2014Pooled it
- Antithrombotic treatment in atrial fibrillation.Heart (British Cardiac Society) · 2007Guideline
- Epidemiological Characteristics of Atrial Fibrillation in Southern China: Results from the Guangzhou Heart Study.Scientific reports · 2018Trial
- Outcomes and costs of left atrial appendage closure from randomized controlled trial and real-world experience relative to oral anticoagulation.European heart journal · 2016Trial
- RHYTHM-AF: design of an international registry on cardioversion of atrial fibrillation and characteristics of participating centers.BMC cardiovascular disorders · 2012Trial
- Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation.Heart (British Cardiac Society) · 2012Trial
- The Use of Direct Oral Anticoagulants (DOACs) in Older Adults Receiving Multidose Drug Dispensing; Interactions, Anticholinergic and Fall-Risk Increasing Drugs.Geriatrics (Basel, Switzerland) · 2026Article
- Association of income and educational levels on initiation of oral anticoagulant therapy in patients with incident atrial fibrillation: A Finnish nationwide cohort study.British journal of clinical pharmacology · 2023Article
- Management and Anticoagulation Treatment of Non-Valvular Atrial Fibrillation in Elderly Patients: The Dali Study.International journal of general medicine · 2023Article
- Acute Ischaemia of the Tongue, a Thromboembolic Event as the First Presentation of Undiagnosed Atrial Fibrillation.Journal of maxillofacial and oral surgery · 2022Article
- The Association Between Clopidogrel and Gastrointestinal Bleeding After Primary Total Joint Arthroplasty.Arthroplasty today · 2021Article
- Observational
- Article
- Molecular basis of arrhythmic substrate in ageing murine peroxisome proliferator-activated receptor γ co-activator deficient hearts modelling mitochondrial dysfunction.Bioscience reports · 2019Article
- CATCH-22: a manual bladder washout protocol to improve care for clot retention.World journal of urology · 2018Article
- Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies.BMJ (Clinical research ed.) · 2018Article
- Trend of Prevalence of Atrial Fibrillation and use of Oral Anticoagulation Therapy in Patients With Atrial Fibrillation in South Korea (2002-2013).Journal of epidemiology · 2018Article
- Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation.Oncotarget · 2017Article
- Age-dependent atrial arrhythmic phenotype secondary to mitochondrial dysfunction in Pgc-1β deficient murine hearts.Mechanisms of ageing and development · 2017Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
objectivesTo examine trends in the prevalence of diagnosed atrial fibrillation (AF), its treatment with oral anticoagulants between 1994 and 2003, and predictors of anticoagulant treatment in 2003.
methodsAnalysis of electronic data from 131 general practices (about one million registered patients annually) contributing to the DIN-LINK database.
resultsFrom 1994 to 2003 the prevalence of "active" AF rose from 0.78% to 1.31% in men and from 0.79% to 1.15% in women. The proportion of patients with AF taking anticoagulants rose from 25% to 53% in men and from 21% to 40% in women. Most others received antiplatelets. The likelihood of receiving anticoagulants was greater for men and with increasing stroke risk. It decreased sharply with age after 75 years. Socioeconomic status, urbanisation and region had no influence. Non-steroidal anti-inflammatory drugs, antiplatelet drugs and ulcer healing drugs were associated with reduced likelihood of receiving anticoagulants, as were peptic ulcers, chronic gut disorders, anaemias, psychoses and poor compliance. Anticoagulant treatment was associated with several cardiovascular co-morbidities and drugs, possibly due to secondary care treatment. Nevertheless, only 56.5% of patients at very high risk of stroke were taking anticoagulants in 2003, whereas 38.2% of patients at low risk of stroke received anticoagulants.
conclusionsThis study confirms previously observed trends of increasing AF prevalence and warfarin treatment. Many patients who may benefit from anticoagulation still do not receive it, whereas others at lower risk of stroke do. The lower likelihood of women receiving anticoagulants is of particular concern.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.